HEM Pharma Inc. (KOSDAQ:376270)

HEM Pharma Statistics

Total Valuation

HEM Pharma has a market cap or net worth of KRW 451.10 billion. The enterprise value is 456.80 billion.

Market Cap	451.10B
Enterprise Value	456.80B

Important Dates

The next estimated earnings date is Thursday, May 28, 2026.

Earnings Date	May 28, 2026
Ex-Dividend Date	n/a

Share Statistics

HEM Pharma has 7.17 million shares outstanding. The number of shares has increased by 10.69% in one year.

Current Share Class	7.17M
Shares Outstanding	7.17M
Shares Change (YoY)	+10.69%
Shares Change (QoQ)	+1.26%
Owned by Insiders (%)	26.06%
Owned by Institutions (%)	4.35%
Float	4.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	34.76
PB Ratio	86.50
P/TBV Ratio	127.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-19.16
EV / Sales	35.19
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-25.24

Financial Position

The company has a current ratio of 0.56, with a Debt / Equity ratio of 3.69.

Current Ratio	0.56
Quick Ratio	0.38
Debt / Equity	3.69
Debt / EBITDA	n/a
Debt / FCF	-1.06
Interest Coverage	-24.01

Financial Efficiency

Return on equity (ROE) is -151.43% and return on invested capital (ROIC) is -33.35%.

Return on Equity (ROE)	-151.43%
Return on Assets (ROA)	-21.96%
Return on Invested Capital (ROIC)	-33.35%
Return on Capital Employed (ROCE)	-137.32%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.29
Inventory Turnover	9.96

Taxes

In the past 12 months, HEM Pharma has paid 3.62 million in taxes.

Income Tax	3.62M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +190.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+190.37%
50-Day Moving Average	76,410.00
200-Day Moving Average	42,269.25
Relative Strength Index (RSI)	39.24
Average Volume (20 Days)	30,070

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HEM Pharma had revenue of KRW 12.98 billion and -23.84 billion in losses. Loss per share was -3,389.00.

Revenue	12.98B
Gross Profit	624.02M
Operating Income	-15.58B
Pretax Income	-23.72B
Net Income	-23.84B
EBITDA	-12.99B
EBIT	-15.58B
Loss Per Share	-3,389.00

Balance Sheet

The company has 13.78 billion in cash and 19.26 billion in debt, with a net cash position of -5.47 billion or -762.74 per share.

Cash & Cash Equivalents	13.78B
Total Debt	19.26B
Net Cash	-5.47B
Net Cash Per Share	-762.74
Equity (Book Value)	5.21B
Book Value Per Share	702.18
Working Capital	-17.85B

Cash Flow

In the last 12 months, operating cash flow was -8.34 billion and capital expenditures -9.75 billion, giving a free cash flow of -18.10 billion.

Operating Cash Flow	-8.34B
Capital Expenditures	-9.75B
Depreciation & Amortization	2.59B
Net Borrowing	19.73B
Free Cash Flow	-18.10B
FCF Per Share	-2,523.75

Margins

Gross margin is 4.81%, with operating and profit margins of -120.06% and -183.69%.

Gross Margin	4.81%
Operating Margin	-120.06%
Pretax Margin	-182.75%
Profit Margin	-183.69%
EBITDA Margin	-100.07%
EBIT Margin	-120.06%
FCF Margin	n/a

Dividends & Yields

HEM Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.69%
Shareholder Yield	-10.69%
Earnings Yield	-5.29%
FCF Yield	-4.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HEM Pharma has an Altman Z-Score of -0.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.97
Piotroski F-Score	1